Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Topical calcitriol-analogs can reduce hair loss caused by chemotherapy.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.

Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.

JAK inhibitors effectively treat severe alopecia areata with manageable side effects.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

Baricitinib helps regrow hair in teens with severe alopecia areata.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Eliminating senescent cells can prevent and reverse chemotherapy-induced peripheral neuropathy.

CDK4/6 inhibitors may cause hair loss in breast cancer patients.

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

DHL-HisZnNa may help reduce hair loss from chemotherapy, but more research is needed.

Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.

Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Kang-ai injection with platinum-based chemotherapy improves tumor response and immune function while reducing side effects in advanced lung cancer.

New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.

No treatment fully prevents hair loss from chemotherapy yet.

Baricitinib is the most effective treatment for alopecia areata.